Peptide conjugated particles

• US 9,616,113 B2
• Filed: 02/17/2015
• Issued: 04/11/2017
• Est. Priority Date: 08/13/2013
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Shea, Lonnie D., Miller, Stephen D., Yap, Jonathan Woon Teck, Getts, Daniel R., McCarthy, Derrick
• Primary Examiner(s): Halvorson, Mark
• Application Number:
  US14/624,463
• Publication Number:
  US 20150190485A1
• Time in Patent Office: 784 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/577 tolerising response
• CPC Class Codes: A61K 2039/622 non-covalent binding
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/06 : of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 : Antianaemics

Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Claims

1. A composition comprising surface functionalized biodegradable PLG particles comprising encapsulated gliaden or one or more antigenic epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 400 nm to about 800 nm and a zeta potential of about −

75 mV to about −

50 mV.

2. The composition of claim 1, wherein the gliadin or one or more antigenic gliaden epitopes comprises one or more of the sequences set forth in SEQ ID NOS:

1295-1724, 1726-1766, and 4983-5440.

3. The composition of claim 1, wherein the particles have a zeta potential of about −

50 mV.

4. The composition of claim 1, wherein the particles have a diameter of about 600 nm.

5. The composition of claim 1, further comprising pharmaceutically acceptable excipients.

6. The particles of claim 1 wherein the surface functionalization is carboxylation.

7. The composition of claim 6 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

8. A lyophilized composition comprising surface functionalized biodegradable poly(lactide-co-glycolide)(PLG) particles comprising encapsulated gliaden or one or more antigenic gliaden epitopes, wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 400 nm to about 1100 nm and a zeta potential of about 75 mV to about −

50 mV.

9. The lyophilized composition of claim 8 wherein the one or more antigenic gliaden epitopes comprises one or more of the sequences set forth in SEQ ID NOS:

1295-1724, 1726-1766, and 4983-5440.

10. The lyophilized composition of claim 8, wherein the surface functionalization is carboxylation.

11. The lyophilized composition of claim 10 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

12. The lyophilized composition of claim 8, wherein the particles have a zeta potential of about −

70 mV.

13. The lyophilized composition of claim 8, wherein the particles have a diameter of about 1100 nm.